PriceTargets.com logo

Janux Therapeutics - JANX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $66.44
  • Forecasted Upside: 35.71%
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$48.96 As of 11/20/2024 01:00 AM ET
▼ -0.05 (-0.10%)

This chart shows the closing price for JANX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Janux Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for JANX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for JANX

Analyst Price Target is $66.44
▲ +35.71% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Janux Therapeutics in the last 3 months. The average price target is $66.44, with a high forecast of $100.00 and a low forecast of $42.00. The average price target represents a 35.71% upside from the last price of $48.96.

This chart shows the closing price for JANX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 10 polled investment analysts is to moderate buy stock in Janux Therapeutics. This rating has held steady since May 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/14/2024William BlairReiterated RatingOutperform
11/7/2024HC WainwrightReiterated RatingBuy ➝ Buy$63.00 ➝ $63.00
11/7/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$100.00 ➝ $100.00
10/24/2024UBS GroupInitiated CoverageBuy$69.00
9/16/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$100.00 ➝ $100.00
9/6/2024Stifel NicolausInitiated CoverageBuy$70.00
8/19/2024HC WainwrightReiterated RatingBuy ➝ Buy$63.00 ➝ $63.00
8/9/2024ScotiabankLower TargetSector Perform ➝ Sector Perform$47.00 ➝ $42.00
8/8/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$100.00 ➝ $100.00
8/8/2024WedbushReiterated RatingOutperform ➝ Outperform$74.00 ➝ $74.00
5/30/2024ScotiabankInitiated CoverageSector Perform$47.00
5/13/2024HC WainwrightBoost TargetBuy ➝ Buy$50.00 ➝ $63.00
5/9/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$100.00
5/8/2024WedbushBoost TargetOutperform ➝ Outperform$53.00 ➝ $74.00
4/16/2024JonestradingInitiated CoverageBuy$70.00
3/21/2024BTIG ResearchInitiated CoverageBuy$62.00
3/20/2024Cantor FitzgeraldInitiated CoverageOverweight$100.00
3/13/2024Bank of AmericaBoost TargetBuy ➝ Buy$24.00 ➝ $48.00
3/11/2024WedbushReiterated RatingOutperform$53.00
2/27/2024William BlairReiterated RatingOutperform
2/27/2024WedbushBoost TargetOutperform ➝ Outperform$24.00 ➝ $53.00
11/13/2023HC WainwrightReiterated RatingBuy ➝ Buy$35.00
11/8/2023WedbushReiterated RatingOutperform ➝ Outperform$24.00
8/10/2023WedbushReiterated RatingOutperform ➝ Outperform$24.00
8/9/2023HC WainwrightReiterated RatingBuy ➝ Buy$35.00
7/18/2023HC WainwrightReiterated RatingBuy ➝ Buy$35.00
7/18/2023WedbushReiterated RatingOutperform ➝ Outperform$24.00
4/5/2023WedbushInitiated CoverageOutperform$24.00
3/17/2023Bank of AmericaLower Target$29.00 ➝ $26.00
3/13/2023HC WainwrightReiterated RatingBuy$35.00
11/14/2022William BlairInitiated CoverageOutperform
7/6/2021Bank of AmericaInitiated CoverageBuy$35.00
7/6/2021CowenInitiated CoverageOutperform
7/6/2021Evercore ISIInitiated CoverageOutperform$35.00
7/6/2021HC WainwrightInitiated CoverageBuy$35.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.59 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024
  • 5 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
5/24/2024
  • 5 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 3 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 7 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
8/22/2024
  • 10 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 10 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 8 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 8 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Janux Therapeutics logo
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $48.96
Low: $47.61
High: $49.33

50 Day Range

MA: $50.06
Low: $43.45
High: $55.95

52 Week Range

Now: $48.96
Low: $7.79
High: $65.60

Volume

391,493 shs

Average Volume

708,719 shs

Market Capitalization

$2.57 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.52

Frequently Asked Questions

What sell-side analysts currently cover shares of Janux Therapeutics?

The following equities research analysts have issued research reports on Janux Therapeutics in the last year: Bank of America Co., BTIG Research, Cantor Fitzgerald, HC Wainwright, Jonestrading, Scotiabank, Stifel Nicolaus, UBS Group AG, Wedbush, and William Blair.
View the latest analyst ratings for JANX.

What is the current price target for Janux Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Janux Therapeutics in the last year. Their average twelve-month price target is $66.44, suggesting a possible upside of 35.7%. Cantor Fitzgerald has the highest price target set, predicting JANX will reach $100.00 in the next twelve months. Scotiabank has the lowest price target set, forecasting a price of $42.00 for Janux Therapeutics in the next year.
View the latest price targets for JANX.

What is the current consensus analyst rating for Janux Therapeutics?

Janux Therapeutics currently has 1 hold rating and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for JANX.

What other companies compete with Janux Therapeutics?

Other companies that are similar to Janux Therapeutics include Scholar Rock, DICE Therapeutics, Pandion Therapeutics, Praxis Precision Medicines and IGM Biosciences. Learn More about companies similar to Janux Therapeutics.

How do I contact Janux Therapeutics' investor relations team?

The company's listed phone number is 858-751-4493 and its investor relations email address is [email protected]. The official website for Janux Therapeutics is www.januxrx.com. Learn More about contacing Janux Therapeutics investor relations.